Search

Your search keyword '"Budhu, Anuradha"' showing total 306 results
Start Over Author "Budhu, Anuradha"
306 results on '"Budhu, Anuradha"'

1. Characterization of tumor evolution by functional clonality and phylogenetics in hepatocellular carcinoma

Author

Kacar, Zeynep, Slud, Eric, Levy, Doron, Candia, Julián, Budhu, Anuradha, Forgues, Marshonna, Wu, Xiaolin, Raziuddin, Arati, Tran, Bao, Shetty, Jyoti, Pomyen, Yotsawat, Chaisaingmongkol, Jittiporn, Rabibhadana, Siritida, Pupacdi, Benjarath, Bhudhisawasdi, Vajarabhongsa, Lertprasertsuke, Nirush, Auewarakul, Chirayu, Sangrajrang, Suleeporn, Mahidol, Chulabhorn, Ruchirawat, Mathuros, and Wang, Xin Wei

Published
2024
Full Text
View/download PDF

3. Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing

Author

Craig, Amanda J., Silveira, Maruhen A. Datsch, Ma, Lichun, Revsine, Mahler, Wang, Limin, Heinrich, Sophia, Rae, Zachary, Ruchinskas, Allison, Dadkhah, Kimia, Do, Whitney, Behrens, Shay, Mehrabadi, Farid R., Dominguez, Dana A., Forgues, Marshonna, Budhu, Anuradha, Chaisaingmongkol, Jittiporn, Hernandez, Jonathan M., Davis, Jeremy L., Tran, Bao, Marquardt, Jens U., Ruchirawat, Mathuros, Kelly, Michael, Greten, Tim F., and Wang, Xin W.

Published
2023
Full Text
View/download PDF

4. Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma

Author

Pomyen, Yotsawat, Chaisaingmongkol, Jittiporn, Rabibhadana, Siritida, Pupacdi, Benjarath, Sripan, Donlaporn, Chornkrathok, Chidchanok, Budhu, Anuradha, Budhisawasdi, Vajarabhongsa, Lertprasertsuke, Nirush, Chotirosniramit, Anon, Pairojkul, Chawalit, Auewarakul, Chirayu U., Ungtrakul, Teerapat, Sricharunrat, Thaniya, Phornphutkul, Kannikar, Sangrajang, Suleeporn, Loffredo, Christopher A., Harris, Curtis C., Mahidol, Chulabhorn, Wang, Xin Wei, and Ruchirawat, Mathuros

Published
2023
Full Text
View/download PDF

5. The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand.

Author

Pupacdi, Benjarath, Loffredo, Christopher A., Budhu, Anuradha, Rabibhadana, Siritida, Bhudhisawasdi, Vajarabhongsa, Pairojkul, Chawalit, Sukeepaisarnjaroen, Wattana, Pugkhem, Ake, Luvira, Vor, Lertprasertsuke, Nirush, Chotirosniramit, Anon, Auewarakul, Chirayu U., Ungtrakul, Teerapat, Sricharunrat, Thaniya, Sangrajrang, Suleeporn, Phornphutkul, Kannika, Albert, Paul S., Kim, Sungduk, Harris, Curtis C., and Mahidol, Chulabhorn

Subjects
LIVER flukes, VIRAL hepatitis, HEPATOCELLULAR carcinoma, VIRUS diseases, AGRICULTURE
Abstract

Thailand is among countries with the highest global incidence and mortality rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). While viral hepatitis and liver fluke infections have been associated with HCC and iCCA, respectively, other environmental risk factors, overall risk factor commonality and combinatorial roles, and effects on survival have not been systematically examined. We conducted a TIGER‐LC consortium‐based population study covering all high‐incidence areas of both malignancies across Thailand: 837 HCC, 1474 iCCA, and 1112 controls (2011–2019) were comprehensively queried on lifelong environmental exposures, lifestyle, and medical history. Multivariate logistic regression and Cox proportional hazards analyses were used to evaluate risk factors and associated survival patterns. Our models identified shared risk factors between HCC and iCCA, such as viral hepatitis infection, liver fluke infection, and diabetes, including novel and shared associations of agricultural pesticide exposure (OR range of 1.50; 95% CI: 1.06–2.11 to 2.91; 95% CI: 1.82–4.63) along with vulnerable sources of drinking water. Most patients had multiple risk factors, magnifying their risk considerably. Patients with lower risk levels had better survival in both HCC (HR 0.78; 95% CI: 0.64–0.96) and iCCA (HR 0.84; 95% CI: 0.70–0.99). Risk factor co‐exposures and their common associations with HCC and iCCA in Thailand emphasize the importance for future prevention and control measures, especially in its large agricultural sector. The observed mortality patterns suggest ways to stratify patients for anticipated survivorship and develop plans to support medical care of longer‐term survivors, including behavioral changes to reduce exposures. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma

Author

Liu, Jinping, Tang, Wei, Budhu, Anuradha, Forgues, Marshonna, Hernandez, Maria O., Candia, Julián, Kim, Yujin, Bowman, Elise D., Ambs, Stefan, Zhao, Yongmei, Tran, Bao, Wu, Xiaolin, Koh, Christopher, Surana, Pallavi, Liang, T. Jake, Guarnera, Maria, Mann, Dean, Rajaure, Manoj, Greten, Tim F., Wang, Zhanwei, Yu, Herbert, and Wang, Xin Wei

Published
2020
Full Text
View/download PDF

10. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma

Author

Chaisaingmongkol, Jittiporn, Budhu, Anuradha, Dang, Hien, Rabibhadana, Siritida, Pupacdi, Benjarath, Kwon, So Mee, Forgues, Marshonna, Pomyen, Yotsawat, Bhudhisawasdi, Vajarabhongsa, Lertprasertsuke, Nirush, Chotirosniramit, Anon, Pairojkul, Chawalit, Auewarakul, Chirayu U., Sricharunrat, Thaniya, Phornphutkul, Kannika, Sangrajrang, Suleeporn, Cam, Maggie, He, Ping, Hewitt, Stephen M., Ylaya, Kris, Wu, Xiaolin, Andersen, Jesper B., Thorgeirsson, Snorri S., Waterfall, Joshua J., Zhu, Yuelin J., Walling, Jennifer, Stevenson, Holly S., Edelman, Daniel, Meltzer, Paul S., Loffredo, Christopher A., Hama, Natsuko, Shibata, Tatsuhiro, Wiltrout, Robert H., Harris, Curtis C., Mahidol, Chulabhorn, Ruchirawat, Mathuros, and Wang, Xin W.

Published
2017
Full Text
View/download PDF

15. Tumor Biology and Immune Infiltration Define Primary Liver Cancer Subsets Linked to Overall Survival After Immunotherapy

Author

Budhu, Anuradha, Pehrsson, Erica C, He, Aiwu, Goyal, Lipika, Kelley, Robin Kate, Dang, Hien, Xie, Changqing, Monge, Cecilia, Tandon, Mayank, Ma, Lichun, Revsine, Mahler, Kuhlman, Laura, Zhang, Karen, Baiev, Islam, Lamm, Ryan, Patel, Keyur, Kleiner, David E, Hewitt, Stephen M, Tran, Bao, Shetty, Jyoti, Wu, Xiaolin, Zhao, Yongmei, Shen, Tsai-Wei, Choudhari, Sulbha, Kriga, Yuliya, Ylaya, Kris, Warner, Andrew C, Edmondson, Elijah F, Forgues, Marshonna, Greten, Tim F, Wang, Xin Wei, Budhu, Anuradha, Pehrsson, Erica C, He, Aiwu, Goyal, Lipika, Kelley, Robin Kate, Dang, Hien, Xie, Changqing, Monge, Cecilia, Tandon, Mayank, Ma, Lichun, Revsine, Mahler, Kuhlman, Laura, Zhang, Karen, Baiev, Islam, Lamm, Ryan, Patel, Keyur, Kleiner, David E, Hewitt, Stephen M, Tran, Bao, Shetty, Jyoti, Wu, Xiaolin, Zhao, Yongmei, Shen, Tsai-Wei, Choudhari, Sulbha, Kriga, Yuliya, Ylaya, Kris, Warner, Andrew C, Edmondson, Elijah F, Forgues, Marshonna, Greten, Tim F, and Wang, Xin Wei

Abstract

Primary liver cancer is a rising cause of cancer deaths in the US. Although immunotherapy with immune checkpoint inhibitors induces a potent response in a subset of patients, response rates vary among individuals. Predicting which patients will respond to immune checkpoint inhibitors is of great interest in the field. In a retrospective arm of the National Cancer Institute Cancers of the Liver: Accelerating Research of Immunotherapy by a Transdisciplinary Network (NCI-CLARITY) study, we use archived formalin-fixed, paraffin-embedded samples to profile the transcriptome and genomic alterations among 86 hepatocellular carcinoma and cholangiocarcinoma patients prior to and following immune checkpoint inhibitor treatment. Using supervised and unsupervised approaches, we identify stable molecular subtypes linked to overall survival and distinguished by two axes of aggressive tumor biology and microenvironmental features. Moreover, molecular responses to immune checkpoint inhibitor treatment differ between subtypes. Thus, patients with heterogeneous liver cancer may be stratified by molecular status indicative of treatment response to immune checkpoint inhibitors.

Published
2023

16. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.

Author

Monge, Cecilia, Xie, Changqing, Myojin, Yuta, Coffman‐D'Annibale, Kelley L., Hrones, Donna, Brar, Gagandeep, Wang, Sophie, Budhu, Anuradha, Figg, William D., Cam, Maggie, Finney, Richard, Levy, Elliot B., Kleiner, David E., Steinberg, Seth M., Wang, Xin Wei, Redd, Bernadette, Wood, Bradford J., and Greten, Tim F.

Subjects
IMMUNE checkpoint inhibitors, BILIARY tract, CATHETER ablation, BILIARY tract cancer, PROGRESSION-free survival
Abstract

Background: Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study was to explore the efficacy and safety of durvalumab (anti‐PD‐L1) and tremelimumab (anti‐CTLA‐4), with and without an interventional radiology (IR) procedure in advanced BTC. Methods: Eligible patients with advanced BTC who had received or refused at least one prior line of systemic therapy were treated with tremelimumab and durvalumab for four combined doses followed by monthly durvalumab alone with and without an IR procedure until the progression of disease or unacceptable toxicity. Objective response was assessed through CT or MRI by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) every 8 weeks. Adverse events (AEs) were recorded and managed. The primary endpoint was 6‐month progression‐free survival (PFS). Results: Twenty‐three patients with advanced BTC were enrolled; 17 patients were assigned to treatment with durvalumab and tremelimumab (Durva/Treme); and 6 patients were treated with the combination of durvalumab, tremelimumab plus IR procedure (Durva/Treme + IR). The best clinical responses in the Durva/Treme arm were partial response (n = 1), stable disease (n = 5), progressive disease (n = 5), and in the Durva/Treme + IR arm: partial response (n = 0), stable disease (n = 3), progressive disease (n = 3). The median PFS was 2.2 months (95% CI: 1.3–3.1 months) in the Durva/Treme arm and 2.9 months (95% CI: 1.9–4.7 months) in the Durva/Treme + IR arm (p = 0.27). The median OS was 5.1 months (95% CI: 2.5–6.9 months) in the Durva/Treme arm and 5.8 months (95% CI: 2.9–40.1 months) in the Durva/Treme + IR arm (p = 0.31). The majority of AEs were grades 1–2. Conclusion: Durva/Treme and Durva/Treme + IR showed similar efficacy. With a manageable safety profile. Larger studies are needed to fully characterize the efficacy of Durva/Treme ± IR in advanced BTC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

Author

Budhu, Anuradha, primary, Pehrsson, Erica C., additional, He, Aiwu, additional, Goyal, Lipika, additional, Kelley, Robin Kate, additional, Dang, Hien, additional, Xie, Changqing, additional, Monge, Cecilia, additional, Tandon, Mayank, additional, Ma, Lichun, additional, Revsine, Mahler, additional, Kuhlman, Laura, additional, Zhang, Karen, additional, Baiev, Islam, additional, Lamm, Ryan, additional, Patel, Keyur, additional, Kleiner, David E., additional, Hewitt, Stephen M., additional, Tran, Bao, additional, Shetty, Jyoti, additional, Wu, Xiaolin, additional, Zhao, Yongmei, additional, Shen, Tsai-Wei, additional, Choudhari, Sulbha, additional, Kriga, Yuliya, additional, Ylaya, Kris, additional, Warner, Andrew C., additional, Edmondson, Elijah F., additional, Forgues, Marshonna, additional, Greten, Tim F., additional, and Wang, Xin Wei, additional

Published
2023
Full Text
View/download PDF

19. Supplementary Table S2 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer

Author

Zhang, Geng, primary, He, Peijun, primary, Tan, Hanson, primary, Budhu, Anuradha, primary, Gaedcke, Jochen, primary, Ghadimi, B. Michael, primary, Ried, Thomas, primary, Yfantis, Harris G., primary, Lee, Dong H., primary, Maitra, Anirban, primary, Hanna, Nader, primary, Alexander, H. Richard, primary, and Hussain, S. Perwez, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S2 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer

Author

Zhang, Geng, primary, He, Peijun, primary, Tan, Hanson, primary, Budhu, Anuradha, primary, Gaedcke, Jochen, primary, Ghadimi, B. Michael, primary, Ried, Thomas, primary, Yfantis, Harris G., primary, Lee, Dong H., primary, Maitra, Anirban, primary, Hanna, Nader, primary, Alexander, H. Richard, primary, and Hussain, S. Perwez, primary

Published
2023
Full Text
View/download PDF

22. Data from Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett's-Associated Esophageal Adenocarcinoma

Author

Nguyen, Giang Huong, primary, Schetter, Aaron J., primary, Chou, David B., primary, Bowman, Elise D., primary, Zhao, Ronghua, primary, Hawkes, Jason E., primary, Mathé, Ewy A., primary, Kumamoto, Kensuke, primary, Zhao, Yiqiang, primary, Budhu, Anuradha, primary, Hagiwara, Nobutoshi, primary, Wang, Xin Wei, primary, Miyashita, Masao, primary, Casson, Alan G., primary, and Harris, Curtis C., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival

Author

Mathé, Ewy A., primary, Nguyen, Giang Huong, primary, Bowman, Elise D., primary, Zhao, Yiqiang, primary, Budhu, Anuradha, primary, Schetter, Aaron J., primary, Braun, Rosemary, primary, Reimers, Mark, primary, Kumamoto, Kensuke, primary, Hughes, Duncan, primary, Altorki, Nasser K., primary, Casson, Alan G., primary, Liu, Chang-Gong, primary, Wang, Xin Wei, primary, Yanaihara, Nozomu, primary, Hagiwara, Nobutoshi, primary, Dannenberg, Andrew J., primary, Miyashita, Masao, primary, Croce, Carlo M., primary, and Harris, Curtis C., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Materials and Methods from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer

Author

Zhang, Geng, primary, He, Peijun, primary, Tan, Hanson, primary, Budhu, Anuradha, primary, Gaedcke, Jochen, primary, Ghadimi, B. Michael, primary, Ried, Thomas, primary, Yfantis, Harris G., primary, Lee, Dong H., primary, Maitra, Anirban, primary, Hanna, Nader, primary, Alexander, H. Richard, primary, and Hussain, S. Perwez, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett's-Associated Esophageal Adenocarcinoma

Author

Nguyen, Giang Huong, primary, Schetter, Aaron J., primary, Chou, David B., primary, Bowman, Elise D., primary, Zhao, Ronghua, primary, Hawkes, Jason E., primary, Mathé, Ewy A., primary, Kumamoto, Kensuke, primary, Zhao, Yiqiang, primary, Budhu, Anuradha, primary, Hagiwara, Nobutoshi, primary, Wang, Xin Wei, primary, Miyashita, Masao, primary, Casson, Alan G., primary, and Harris, Curtis C., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures 1-3, Table 1 from A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients

Author

Roessler, Stephanie, primary, Jia, Hu-Liang, primary, Budhu, Anuradha, primary, Forgues, Marshonna, primary, Ye, Qing-Hai, primary, Lee, Ju-Seog, primary, Thorgeirsson, Snorri S., primary, Sun, Zhongtang, primary, Tang, Zhao-You, primary, Qin, Lun-Xiu, primary, and Wang, Xin Wei, primary

Published
2023
Full Text
View/download PDF

37. A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma

Author

Monge, Cecilia, primary, Pehrsson, Erica C, additional, Xie, Changqing, additional, Duffy, Austin G, additional, Mabry, Donna, additional, Wood, Bradford J, additional, Kleiner, David E, additional, Steinberg, Seth M, additional, Figg, William D, additional, Redd, Bernadette, additional, Budhu, Anuradha, additional, Wang, Sophie, additional, Tandon, Mayank, additional, Ma, Lichun, additional, Wei Wang, Xin, additional, and Greten, Tim F, additional

Published
2022
Full Text
View/download PDF

40. Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study

Author

Wang, Zhanwei, primary, Budhu, Anuradha S, additional, Shen, Yi, additional, Wong, Linda Lou, additional, Hernandez, Brenda Y, additional, Tiirikainen, Maarit, additional, Ma, Xiaomei, additional, Irwin, Melinda L, additional, Lu, Lingeng, additional, Zhao, Hongyu, additional, Lim, Joseph K, additional, Taddei, Tamar, additional, Mishra, Lopa, additional, Pawlish, Karen, additional, Stroup, Antoinette, additional, Brown, Robert, additional, Nguyen, Mindie H, additional, Koshiol, Jill, additional, Hernandez, Maria O, additional, Forgues, Marshonna, additional, Yang, Hwai‐I, additional, Lee, Mei‐Hsuan, additional, Huang, Yu‐Han, additional, Iwasaki, Motoki, additional, Goto, Atsushi, additional, Suzuki, Shiori, additional, Matsuda, Koichi, additional, Tanikawa, Chizu, additional, Kamatani, Yoichiro, additional, Mann, Dean, additional, Guarnera, Maria, additional, Shetty, Kirti, additional, Thomas, Claire E, additional, Yuan, Jian‐Min, additional, Khor, Chiea Chuen, additional, Koh, Woon‐Puay, additional, Risch, Harvey, additional, Wang, Xin Wei, additional, and Yu, Herbert, additional

Published
2021
Full Text
View/download PDF

41. MicroRNA expression, survival, and response to interferon in liver cancer

Author

Junfang Ji, Jiong Shi, Budhu, Anuradha, Zhipeng Yu, Forgues, Marshonna, Roessler, Stephanie, Ambs, Stefan, Chen, Yidong, Meltzer, Paul S., Croce, Carlo M., Lun-Xiu Qin, Man, Kwan, Chung-Mau Lo, Lee, Joyce, Ng, Irene O.L., Fan, Jia, Zhao-You Tang, Hui-Chuan Sun, and Xin Wei Wang

Subjects
RNA -- Physiological aspects, Interferon alpha -- Usage, Liver cancer -- Care and treatment, Cancer patients -- Health aspects, Men -- Health aspects, Women -- Health aspects
Abstract

The study aims to investigate the microRNA expression, survival rate and response to interferon alfa in the case of men and women with liver cancer. The results indicate that there was a difference in expression patterns of microRNA among men and women with the ailment; and also that patients with low miR-26 had a shorter survival rate but a better response to interferon therapy.

Published
2009

42. Abstract 2658: Oncogenicity of adeno-associated virus (AAV) integration into the genomes of liver cancer patients depends on the overlap between the AAV integration site and the AAV X gene

Author

Schaffer, Alejandro A., primary, Dominguez, Dana, additional, Gertz, E. M., additional, Chapman, Lesley M., additional, Budhu, Anuradha, additional, Forgues, Marshonna, additional, Chaisaingmongkol, Jittiporn, additional, Rabibhadana, Siritida, additional, Pupacdi, Benjarath, additional, Wu, Xiaolin, additional, Harris, Curtis C., additional, Ruchirawat, Mathuros, additional, Ruppin, Eytan, additional, and Wang, Xin W., additional

Published
2021
Full Text
View/download PDF

48. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma

Author

Oishi, Naoki, Kumar, Mia R., Roessler, Stephanie, Ji, Junfang, Forgues, Marshonna, Budhu, Anuradha, Zhao, Xuelian, Andersen, Jesper B., Ye, Qing-Hai, Jia, Hu-Liang, Qin, Lun-Xiu, Yamashita, Taro, Woo, Hyun Goo, Kim, Yoon Jun, Kaneko, Shuichi, Tang, Zhao-You, Thorgeirsson, Snorri S., and Wang, Xin Wei

Published
2012
Full Text
View/download PDF

49. Loss of MiR-192-5p Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma.

Author

Gu, Yuanzhuo, primary, Ji, Fubo, additional, Liu, Niya, additional, Zhao, Yongzhi, additional, Wei, Xiyang, additional, Hu, Shiyuan, additional, Jia, Wei, additional, Wang, Xin Wei, additional, Budhu, Anuradha, additional, Ji, Juling, additional, Zhao, Bin, additional, Roessler, Stephanie, additional, Zheng, Xin, additional, and Ji, Junfang, additional

Published
2020
Full Text
View/download PDF

50. Loss of MiR-192 Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma

Author

Gu, Yuanzhuo, primary, Ji, Fubo, additional, Liu, Niya, additional, Zhao, Yongzhi, additional, Wei, Xiyang, additional, Hu, Shiyuan, additional, Jia, Wei, additional, Wang, Xin Wei, additional, Budhu, Anuradha, additional, Ji, Juling, additional, Zhao, Bin, additional, Roessler, Stephanie, additional, Zheng, Xin, additional, and Ji, Junfang, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results